Emrelis (telisotuzumab vedotin-tllv)
Emrelis (telisotuzumab vedotin) has FDA accelerated approval for adults with advanced non-squamous lung cancer with high c-Met protein levels after prior systemic therapy. Not available where you live? Your doctor may be able to request it by named-patient import. Reserve Meds coordinates the US supply and paperwork and quotes your costs in writing first.
Previously-treated c-Met-overexpressing NSCLC ยท Oncology (NSCLC ADC)
Ask about Emrelis
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Emrelis
Emrelis (telisotuzumab vedotin-tllv) is a specialty medicine manufactured by AbbVie, used in the treatment of Previously-treated c-Met-overexpressing NSCLC. It received FDA approval in 2025 under the FDA accelerated May 2025 pathway.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Note: First c-Met ADC. No EMA MAA filed as of June 2025 per everyone.org.
Accessing Emrelis through Reserve Meds
We help patients in the Middle East, India, Pakistan, Africa, and other regions access Emrelis via established Named Patient Program (NPP) and personal-import pathways. Every order requires a prescription from a licensed physician in the destination country.
What we need from you
- A prescription from a licensed physician in your country of residence.
- A clinical justification from the prescribing physician (why Emrelis for this patient).
- Destination-country NPP or personal-import paperwork (we help prepare these).
- Patient consent for cross-border drug import under the applicable pathway.
Typical timeline
We give you a written timeline estimate for your case before you commit. Timing varies by destination country regulatory review speed and physician documentation turnaround.
Indication context
Emrelis is indicated for Previously-treated c-Met-overexpressing NSCLC. The condition falls within Oncology (NSCLC ADC). For patients with this condition in countries where Emrelis is not yet registered, NPP access is typically the primary legal pathway for obtaining treatment.
About the manufacturer
Emrelis is manufactured by AbbVie. We source drug supply exclusively through a US-licensed pharmaceutical wholesale partner, ensuring every unit is authentic, serialized, and chain-of-custody documented.
International regulatory status
- United States: FDA approved (2025).
- EMA (EU): Not approved.
- MHRA (UK): Not approved.
- Other countries: Approval status varies. Reserve Meds coordinates access under each destination country's NPP pathway.
Start a request for Emrelis
If you or a family member needs Emrelis and it is not available in your country, submit a request. Our clinical team will review eligibility and reach out within one business day.
Emrelis, country access pages
Information on how patients in different countries access Emrelis through Named Patient Program pathways.
- Emrelis in United Arab Emirates, The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.
- Emrelis in Saudi Arabia, The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.
- Emrelis in India, India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.
- Emrelis in Kuwait, Kuwait's Ministry of Health operates a Personal Import pathway for specialty drugs not registered locally, typically through a hospital pharmacy with physician attestation.
- Emrelis in Qatar, Qatar's MoPH permits unregistered drug import under a named-patient pathway with physician and MoPH approval; Hamad Medical Corp frequently sponsors.
- Emrelis in Bahrain, Bahrain's NHRA accepts named-patient import requests for rare-disease and specialty drugs not registered locally.
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at pv@reservemeds.com. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 (see Trust & Compliance).
Access by country
Reserve Meds publishes a detailed country deep-dive for Emrelis in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list telisotuzumab vedotin as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Frequently asked questions
How can I get Emrelis if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Emrelis for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Emrelis through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Emrelis. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Emrelis through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Emrelis to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Emrelis to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Emrelis cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Emrelis?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.